With More Than $1B in the Bank, Alnylam Expects to Surpass Pipeline Guidance | GenomeWeb

Following the consummation of a lucrative research and development alliance with Genzyme and with its acquisition of former rival Sirna Therapeutics pending, Alnylam Pharmaceuticals is now projecting that it will have six to seven drug candidates in the clinic by next year, topping its previous guidance.

Meanwhile, the company is now sitting on more than $1 billion in cash, which Alnylam executives said last week would enable the firm to execute its strategy while still ending 2014 with more than $825 million in its coffers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.